Barclays PLC Sage Therapeutics, Inc. Call Options Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
Call Options
14 transactions
Others Institutions Holding SAGE
# of Institutions
168Shares Held
44.3MCall Options Held
790KPut Options Held
440K-
Madison Avenue Partners, LP New York, NY6.08MShares$52.7 Million5.93% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT1.95MShares$16.9 Million0.07% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.92MShares$16.6 Million0.01% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.52MShares$13.2 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...